Literature DB >> 6277833

Evaluation of misonidazole peripheral neurotoxicity in rats by analysis of nerve trains evoked response.

M S Edwards, C A Bolger, V A Levin, T L Phillips, D L Jewett.   

Abstract

The clinical use of misonidazole and other nitroimidazole radiosensitizing agents is limited by the peripheral and central neurotoxicity that is produced in animals and humans. In a blinded study, rats treated with misonidazole at either 100 mg/kg or 300 mg/kg, 5 days/week for 3 weeks, were evaluated for peripheral neurotoxicity using nerve trains evoked responses. Only one rat treated at a dose of 100 mg/kg developed symptoms and signs of neurotoxicity, while all rats treated at 300 mg/kg developed these signs and symptoms. Nerve trains analysis made possible a diagnosis of neurotoxicity before overt clinical signs appeared. This test is non-invasive and may be useful for evaluating patients receiving nitroimidazole radiosensitizers as part of a radiation therapy regimen.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6277833     DOI: 10.1016/0360-3016(82)90387-x

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  3 in total

1.  Evoked potentials in rats with misonidazole neurotoxicity. I. Brain stem auditory evoked potentials.

Authors:  M S Edwards; S K Powers; R A Baringer; D L Jewett; C Bolger; T L Phillips
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

2.  Misonidazole neurotoxicity in rats: Part I. Evaluation of misonidazole neurotoxicity in rats by analysis of brain stem auditory and cortical evoked potentials.

Authors:  M S Edwards; D G Gordon; V A Levin; T L Phillips
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

3.  Misonidazole neurotoxicity in rats: Part II. Effect of pre- and intermittent treatment with pentobarbital on misonidazole neurotoxicity in the rat.

Authors:  M S Edwards; D G Gordon; A Salamy; V A Levin; T L Phillips
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.